Timothy J. Yeatman

Last updated
Dr. Timothy Yeatman Yeatman Timothy.jpg
Dr. Timothy Yeatman

Timothy Joseph Yeatman, M.D. F.A.C.S. (born June 10, 1958) is currently the Associate Center Director for Translational Research and Innovation for the Tampa General Hospital Cancer Institute and Professor of Surgery at the University of South Florida, United States. He previously served as the Executive Medical Director of Oncologic Services and the Senior Medical Director for the Oncology Clinical Program at Intermountain Healthcare, serving 23 hospitals and >6000 patients across the State of Utah and beyond. He was also Professor of Surgery at the University of Utah and a Member of the Huntsman Cancer Institute's Cellular Response and Regulation Program. Dr Yeatman was also the Director of Gibbs Cancer Center and President of Gibbs Cancer Center & Research Institute in Spartanburg, South Carolina where he founded the Guardian Research Network, a novel approach to clinical data analytics, leveraging the entire EHR for real time database queries for identifying clinical trial candidates. [1] Yeatman held numerous positions at the Moffitt Cancer Center (MCC) in Florida over a 20 year span from 1992 - 2012. Yeatman served as the Associate Center Director for Clinical Investigations, the Associate Center Director for Translational Research, the Executive Vice President for Translational Research, Professor of Surgery and Cncologic Sciences, and the GI Tumor Program Leader at the Moffitt Cancer Center and the University of South Florida. [2] There he led a $100m Moffitt:Merck collaboration and co-founded a novel biotech company, M2Gen. He also served as Chief Scientific Officer for the Center for Advancement of Science in Space (CASIS), a non-profit organization appointed by Congress and funded by NASA to oversee all scientific use of the International Space Station. [3] He has been funded by the National Cancer Institute (NCI) since 1993 and continues to perform basic and translational colorectal cancer research in genomics and biomarker development.

Contents

Background

Yeatman was born in Cheverly, Maryland. He received his undergraduate degree at Duke University, where he graduated summa cum laude and Phi Beta Kappa. He received his medical degree from Emory University and completed his surgical internship and residency at the University of Florida, and then a surgical oncology fellowship at MD Anderson Cancer Center, prior to arriving at Moffitt Cancer Center. [4]

Career and research

Yeatman has been continuously funded by the National Cancer Institute (NCI) since 1993. [5] He spent 20 years at the Moffitt Cancer Center as a physician scientist, with a clinical and research focus on the problems linked to colorectal cancer. He has spent more than 10 years in the field of molecular profiling and gene expression classifier development, working in the environment of team science and multidisciplinary collaboration. Yeatman has active and completed grants funded by NCI as well as the state of Florida. Yeatman holds numerous patents that include the identification of the first human mutations in the SRC oncogene (Patent Number 7803909) [6] and methods for matching patients to clinical trials using a molecular database (Patent Numbers 8175896, 8095389, 20110288890, 20080033658). [7] [8]

Yeatman is a pioneer in personalized medicine, having headed the development of the world's largest human tumor bio-repository and database with comprehensive molecular profiling of approximately 20,000 tumor specimens. He was the principal architect of the Total Cancer Care (TCC) initiative in personalized medicine, and served as the president and founding chief scientific officer of M2Gen (a wholly owned subsidiary of the MCC that implemented and managed the TCC project). [9] He participated in recruiting a nationwide network of 18 hospitals (TCC Consortium) that collected, macrodissected, curated and profiled more than 20,000 snap frozen tumor samples on a single Affymetrix platform with a commercial pipeline. Yeatman also served as chair of the Joint Scientific Committee, and the co-chair of the Joint Operating Committee, which made him the primary liaison with Merck & Co. in developing and managing the more than $150 million project and the derivative science. [10]

Awards and recognition

Yeatman has received numerous honors and awards including the James IV Association of Surgeons Traveling Fellowship, Europe; [11] the Center Director's Award for Outstanding Research at Moffitt Cancer Center; [12] and the James Ewing Foundation Trainee Award, Society of Surgical Oncology, and the Million Dollar Researcher award at the University of South Florida. [13] Yeatman has been continuously funded through additional grants from the American Cancer Society, including a Director's Challenge Award for the global profiling of human colon cancer. [14] He is a member of numerous societies including the American Surgical Association and the Society of Surgical Oncology and the American Association for Cancer Research. He has published around 150 articles in the top peer-reviewed journals in his field, [15] including the prestigious Science , [16] Nature Genetics , [17] Nature Medicine , [18] Nature Reviews Cancer , [19] as well as the Journal of the National Cancer Institute , [20] [21] and Cancer Research ,. [22] [23] [24] [25]

Related Research Articles

<span class="mw-page-title-main">Pancreatic cancer</span> Type of endocrine gland cancer

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known.

The Children's Oncology Group (COG), a clinical trials group supported by the National Cancer Institute (NCI), is the world's largest organization devoted exclusively to pediatric cancer research. The COG conducts a spectrum of clinical research and translational research trials for infants, children, adolescents, and young adults with cancer.

<span class="mw-page-title-main">H. Lee Moffitt Cancer Center & Research Institute</span> Hospital in Florida, United States

Houston Lee Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment and research center located in Tampa, Florida. Established in 1981 by the Florida Legislature, the hospital opened in October 1986 on the University of South Florida's campus. Moffitt is one of two National Cancer Institute-designated Comprehensive Cancer Centers based in Florida. In 2021, U.S. News & World Report ranked Moffitt Cancer Center as a top 30 cancer hospital in the United States.

<span class="mw-page-title-main">Richard Pestell</span> Australian oncologist and endocrinologist

Richard G. Pestell is an Australian American oncologist and endocrinologist who is Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. Pestell was appointed an Officer of the Order of Australia in the 2019 Queen's Birthday Honours for distinguished service to medicine and medical education.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

A Tumor Bank, A Tumor Bank is sometimes also referred to as a Tissue Bank, since normal tissues for research are also often collected. However, this function is distinct from a Tissue Bank which collects and harvests human cadaver tissue for medical research and education, and banks which store Biomedical tissue for organ transplantation.

<span class="mw-page-title-main">John E. Niederhuber</span>

John E. Niederhuber, MD was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.

Wafik El-Deiry is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University, Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously deputy director of Translational Research at Fox Chase Cancer Center, where he was also co-Leader of the Molecular Therapeutics Program.

Src kinase family is a family of non-receptor tyrosine kinases that includes nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. Frk has homologs in invertebrates such as flies and worms, and Src homologs exist in organisms as diverse as unicellular choanoflagellates, but the SrcA and SrcB subfamilies are specific to vertebrates. Src family kinases contain six conserved domains: a N-terminal myristoylated segment, a SH2 domain, a SH3 domain, a linker region, a tyrosine kinase domain, and C-terminal tail.

<span class="mw-page-title-main">Wolfram Samlowski</span> Oncologist

Wolfram Samlowski is an American medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and a member of the Research Developmental Therapeutics and Genitourinary Committees for US Oncology. His research interests include translational research and development of novel cancer immunotherapy agents, translational drug development as well as gene therapy. His clinical interests are in developing more effective treatments for advanced stages of melanoma and non-melanoma skin cancers, and renal cancer.

Arthur L. Jenkins III is an American fellowship-trained neurosurgeon, co-director of the Neurosurgical Spine Program, and Director of Spinal Oncology and Minimally Invasive Spinal Surgery (MIS) Program at the Mount Sinai Hospital, New York. Additionally, he is an associate professor of Neurosurgery and of Orthopedic Surgery at the Mount Sinai School of Medicine. Dr. Jenkins has multiple patents and patent applications for spine-related implants and support systems, and is developing new minimally invasive treatments for patients with cancer that has spread to the spine. He is an innovator in the treatment of acute spinal cord injury as well as degenerative and congenital anomalies of the spine, taking a minimally invasive or minimal-impact approach where possible. He is board certified in Neurological Surgery and is licensed in New York and Connecticut.

<span class="mw-page-title-main">Warren Jackson Pledger</span>

Warren Jackson Pledger is a molecular cell biologist who is the Associate Director for Basic Sciences, Tampa General Hospital Cancer Institute and Professor, Department of Molecular Medicine, Morsani College of Medicine, USF Health in Tampa, Florida. He had been a Professor, Department of Surgery, University of Utah School of Medicine and a member of the Cell Response and Regulation Program, Huntsman Cancer Institute. He was the Associate Center Director for Basic Science at the Moffitt Cancer Center and Research Institute. He has held academic appointments and tenure at the University of North Carolina School of Medicine, Vanderbilt University School of Medicine and the University of South Florida College of Medicine.

Ralph R. Weichselbaum is an American physician specializing in radiation oncology, a member of the Institute of Medicine of the National Academy of Sciences, Ludwig professor, He is Daniel K. Ludwig Distinguished Service Professor of Radiation Oncology and Chairman, Department of Radiation and Cellular Oncology, at the University of Chicago Pritzker School of Medicine, and Head of the University of Chicago Center for Radiation Therapy, and the director of the Chicago Tumor Institute. Weichselbaum is also Co- Director of the Ludwig Center for Metastasis Research at the University of Chicago.

<span class="mw-page-title-main">Thomas P. Loughran Jr.</span> American physician-scientist

Thomas P. Loughran, Jr. is an American physician-scientist who specializes in cancer research and treatment. He became director of the University of Virginia Cancer Center, F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine at the University of Virginia on August 15, 2013. Between 2003 and 2013, Loughran served as the founding director of the Penn State Hershey Cancer Institute and professor of medicine at the Penn State College of Medicine. His previous appointments included program leader of hematologic malignancies at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, associate director of the Bone Marrow Transplant Program at SUNY Health Science Center and chief of hematology at the Syracuse Veteran's Affairs Medical Center in Syracuse, New York. Loughran completed his fellowship in medical oncology in 1985 at the Fred Hutchinson Cancer Research Center in Seattle, Washington under direction of Nobel Laureate E. Donnall Thomas. He remained on faculty there for seven years. Loughran earned his medical degree from Hahnemann Medical School in Philadelphia in 1979.

Dr. Kodaganur S. Gopinath, MS, FAMS, FRCS (Edin) is an Indian surgical oncologist, known for his pioneering work on oncological research. He is a recipient of many awards including Dr. B. C. Roy Award, considered to be the premier medical honour in the country. The President of India recognised his services to the field of oncology, by awarding him the fourth highest civilian award, Padma Shri, in 2010.

Daniel Albo is an American surgeon, medical researcher, and pioneer in minimally invasive gastrointestinal surgical oncology. He has published in areas including laparoscopic colorectal surgery and surgical oncology. He is the director of surgical oncology services and the director of health services research at the Georgia Regents University Cancer Center.

<span class="mw-page-title-main">Triciribine</span> Chemical compound

Triciribine is a cancer drug which was first synthesized in the 1970s and studied clinically in the 1980s and 1990s without success. Following the discovery in the early 2000s that the drug would be effective against tumours with hyperactivated Akt, it is now again under consideration in a variety of cancers. As PTX-200, the drug is currently in two early stage clinical trials in breast cancer and ovarian cancer being conducted by the small molecule drug development company Prescient Therapeutics.

Luis Alberto Diaz, Jr. is the Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine.

<span class="mw-page-title-main">Duane Mitchell</span> American physician and research scientist

Duane A. Mitchell is an American physician-scientist and university professor. He is currently employed at the University of Florida College of Medicine, in Gainesville, Florida as the Assistant Vice President for Research, Associate Dean for Translational Science and Clinical Research, and Director of the University of Florida (UF) Clinical and Translational Science Institute. He is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery. and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy. Mitchell is also the founder, President, and Chairman of iOncologi, Inc., a biotechnology company in Gainesville, FL specializing in immuno-oncology.

A Molecular Tumor Board (MTB) is a dedicated group of medical experts to evaluate hard-to-treat cancers and provide a personalized healthcare opportunity. It has also been called a Sequencing Tumor Board and it is characterized by the in-depth application of molecular analysis for a single patient. Molecular Tumor Boards are considered most useful for cancer types for which therapies are not effective, for example, in the case of heterogeneous sarcomas. The boards are composed by clinical oncologists and pathologists alongside other specialists, which vary from institution to institution, but might include geneticists, bioinformaticians and molecular biologists. MTBs are considered to improve clinical outcomes for patients with tumors with unique molecular profiles.

References

  1. "Meet Our Leadership | Gibbs Cancer Center | Spartanburg, SC | Gibbs Cancer Center". Archived from the original on 2013-10-16. Retrieved 2013-10-16.
  2. 2. http://www.moffitt.org/research--clinical-trials/individual-researchers/timothy-joseph-yeatman-md
  3. "CASIS Names Dr. Timothy J. Yeatman Interim Chief Scientist - CASIS - Center for the Advancement of Science in Space". Archived from the original on 2013-10-21. Retrieved 2013-10-16.
  4. "Archived copy". Archived from the original on 2013-10-17. Retrieved 2013-10-16.{{cite web}}: CS1 maint: archived copy as title (link)
  5. "RePORT ⟩ RePORTER".
  6. http://www.patentfish.com/search.php
  7. http://www.patentfish.com/search.php
  8. "Timothy Yeatman Inventions, Patents and Patent Applications - Justia Patents Search".
  9. "Moffitt promotes Timothy Yeatman to M2Gen chief science officer - Tampa Bay Business Journal". Archived from the original on 2010-09-26.
  10. "Moffitt, Merck break ground on collaborative project - Tampa Bay Business Journal". Archived from the original on 2007-11-17.
  11. "James IV Association of Surgeons | Members".
  12. "Archived copy". Archived from the original on 2013-10-17. Retrieved 2013-10-16.{{cite web}}: CS1 maint: archived copy as title (link)
  13. "Stocks". 17 October 2023.[ dead link ]
  14. "Archived copy". Archived from the original on 2013-10-17. Retrieved 2013-10-16.{{cite web}}: CS1 maint: archived copy as title (link)
  15. "Archived copy" (PDF). Archived from the original (PDF) on 2013-10-17. Retrieved 2013-10-16.{{cite web}}: CS1 maint: archived copy as title (link)
  16. Attallah AM, Yeatman TJ, Noguchi PD, Johnson JB. Antibody-dependent cell-mediated cytotoxicity: detection by automated flow cytometry with ultramicro techniques. Science. 1980 Jul 18;209(4454):404-6. PMID   7384812.
  17. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. Nature Genetics. 1999 Feb;21(2):187-90. PMID   9988270.
  18. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine. 2008 Aug;14(8):822-7. PMID   18641660.
  19. Yeatman TJ. A renaissance for SRC. Nature Reviews Cancer. 2004 Jun;4(6):470-80. Review. PMID   15170449.
  20. Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. Journal of the National Cancer Institute. 2011 Dec 21;103(24):1859-70. PMID   22157961.
  21. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. Journal of the National Cancer Institute. 2002 Apr 3;94(7):513-21. PMID   11929952.
  22. Hegde P, Qi R, Gaspard R, Abernathy K, Dharap S, Earle-Hughes J, Gay C, Nwokekeh NU, Chen T, Saeed AI, Sharov V, Lee NH, Yeatman TJ, Quackenbush J. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Research. 2001 Nov 1;61(21):7792-7. PMID   11691794.
  23. Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Research. 2002 May 1;62(9):2669-74. PMID   11980666.
  24. Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ, Yeatman TJ. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Research. 2003 Aug 1;63(15):4368-74. PMID   12907606.
  25. Irby RB, Malek RL, Bloom G, Tsai J, Letwin N, Frank BC, Verratti K, Yeatman TJ, Lee NH. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Research. 2005 Mar 1;65(5):1814-21. PMID   15753379.